Illumina, Inc. (NASDAQ:ILMN) Given Average Recommendation of "Hold" by Brokerages

Key Points

• Analysts have a consensus rating of "Hold" on Illumina from 18 firms (2 sell, 10 hold, 6 buy) with an average 1‑year price target of $129.69.
• Illumina beat quarterly expectations, reporting $1.35 EPS vs. $1.26 estimate and $1.16B revenue vs. $1.10B, and issued FY2026 guidance of 5.050–5.200 EPS versus analysts' average forecast of 4.51.
• The stock opened at $130.32 (1‑year range $69.83–$155.53) with a $19.8B market cap and a P/E of 23.9; SVP Patricia Leckman sold 2,370 shares, insiders own 0.17% and institutions own 89.42% of the stock.

Illumina, Inc. (NASDAQ:ILMN - Get Free Report) has been assigned a consensus recommendation of "Hold" from the eighteen ratings firms that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and six have given a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $129.6875.

Several research firms have recently weighed in on ILMN. Evercore set a $150.00 price target on shares of Illumina in a research note on Friday, February 6th. Canaccord Genuity Group increased their price target on shares of Illumina from $130.00 to $150.00 and gave the company a "hold" rating in a research note on Monday, January 26th. Stifel Nicolaus increased their price target on shares of Illumina from $135.00 to $155.00 and gave the company a "buy" rating in a research note on Tuesday, January 20th. Robert W. Baird set a $137.00 price target on shares of Illumina in a research note on Friday, February 6th. Finally, Wall Street Zen raised shares of Illumina from a "buy" rating to a "strong-buy" rating in a research note on Saturday, February 14th.

Illumina Stock Performance

Illumina stock opened at $130.32 on Wednesday. The firm has a 50 day simple moving average of $123.57 and a 200-day simple moving average of $124.17. Illumina has a 1-year low of $69.83 and a 1-year high of $155.53. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.08 and a quick ratio of 1.72. The stock has a market cap of $19.80 billion, a price-to-earnings ratio of 23.91, a price-to-earnings-growth ratio of 2.43 and a beta of 1.49.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings results on Thursday, February 5th. The life sciences company reported $1.35 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.09. Illumina had a net margin of 19.57% and a return on equity of 31.04%. The business had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.10 billion. During the same quarter in the prior year, the company posted $0.95 EPS. The business's revenue for the quarter was up 5.0% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.050-5.200 EPS. On average, analysts expect that Illumina will post 4.51 EPS for the current year.

Insider Buying and Selling at Illumina

In related news, SVP Patricia Leckman sold 2,370 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $116.18, for a total transaction of $275,346.60. Following the completion of the transaction, the senior vice president owned 16,321 shares of the company's stock, valued at approximately $1,896,173.78. This trade represents a 12.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.17% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Illumina

A number of hedge funds have recently made changes to their positions in ILMN. Empowered Funds LLC boosted its position in shares of Illumina by 113.7% during the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company's stock worth $737,000 after purchasing an additional 4,940 shares during the period. Sivia Capital Partners LLC purchased a new position in shares of Illumina during the 2nd quarter worth approximately $621,000. CW Advisors LLC purchased a new position in shares of Illumina during the 2nd quarter worth approximately $275,000. Marshall Wace LLP boosted its position in shares of Illumina by 49.0% during the 2nd quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company's stock worth $5,691,000 after purchasing an additional 19,618 shares during the period. Finally, Cresset Asset Management LLC boosted its position in shares of Illumina by 30.9% during the 2nd quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company's stock worth $706,000 after purchasing an additional 1,748 shares during the period. Hedge funds and other institutional investors own 89.42% of the company's stock.

About Illumina

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.